Impersonal Medicine: IC/BPS And How An Orphan Indication Becomes A Common Disease
Executive Summary
US FDA advisory committee recommendation to combine interstitial cystitis and bladder pain syndrome patients in clinical trials is an interesting example of encouraging drug development by broadening the patient population. That runs counter to the personalized medicine mantra of narrowing patient populations based on mechanism of action.